NX-1607: A phase 1 study of NX-1607 in adults with advanced solid tumours

A phase 1 trial testing NX-1607 in people with diffuse large B-cell lymphoma (DLBCL) or transformed chronic lymphocytic leukaemia (CLL).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05107674 

Trial aim and background

The aim of this trial is to evaluate the safety and efficacy of NX-1607 in adults with advanced solid tumours. Phase 1a does not include lymphoma, but phase 1b does include DLBCL and transformed CLL.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with DLBCL or transformed CLL which has not responded to all standard treatment options may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University College London Hospitals NHS Foundation Trust, London
  • Addenbrookes Cambridge University Hospital, Cambridge
  • Beatson West of Scotland Cancer Centre, Glasgow
  • Sarah Cannon Research Institute, London
  • The Christie NHS Foundation Trust, Manchester
  • Northern Centre for Cancer Care, Newcastle
  • Churchill Hospital, Oxford
  • Royal Marsden Hospital NHS Foundation Trust, Sutton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05107674 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.